The acute subjective experience of an altered conscious state is central to treatment outcomes.
There is no translational model to distinguish among different altered states of consciousness.
We’re mapping the biological basis of the varieties of psychedelic experience to enable precision design of modified conscious states.
Our pipeline is based on a combination approach that uses psychedelic “primer” compounds together with non-psychedelic “probe” compounds that modulate the altered state of consciousness produced by the primer.
With the Osmanthus screening platform, we’ve identified six probe candidates to date; each with potentially unique therapeutic utility when combined with the lead primer. Future programs in development include a variety of additional primers and probes.